Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 75% Improvement Relative Risk Recovery 43% Koshak et al. NCT04401202 Nigella Sativa RCT EARLY Is early treatment with nigella sativa beneficial for COVID-19? RCT 183 patients in Saudi Arabia Improved recovery with nigella sativa (p=0.00021) Koshak et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769 Favors nigella sativa Favors control
Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
Koshak et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769, NCT04401202 (history)
Koshak et al., Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial, Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769, NCT04401202
Aug 2021   Source   PDF  
  All Studies   Meta
RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. 500mg Nigella Sativa oil (MARNYS Cuminmar) twice daily for 10 days. NCT04401202 (history).
risk of hospitalization, 74.7% lower, RR 0.25, p = 0.37, treatment 1 of 91 (1.1%), control 4 of 92 (4.3%), NNT 31.
risk of no recovery, 42.7% lower, RR 0.57, p < 0.001, treatment 34 of 91 (37.4%), control 60 of 92 (65.2%), NNT 3.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Koshak et al., 15 Aug 2021, Randomized Controlled Trial, Saudi Arabia, peer-reviewed, 10 authors, trial NCT04401202 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNigella SativaAll
Abstract: Complementary Therapies in Medicine 61 (2021) 102769 Contents lists available at ScienceDirect Complementary Therapies in Medicine journal homepage: Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial Abdulrahman E. Koshak a, *, Emad A. Koshak b, Abdullah F. Mobeireek c, Mazen A. Badawi b, Siraj O. Wali b, Husam M. Malibary b, Ali F. Atwah d, Meshari M. Alhamdan e, Reem A. Almalki b, Tariq A. Madani b a Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University 80260, Jeddah, 21589, Saudi Arabia Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia d Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia e University Medical Services Centre, King Abdulaziz University, Jeddah, Saudi Arabia b c A R T I C L E I N F O A B S T R A C T Keywords: COVID-19 SARS-CoV-2 Herbal medicine Nigella sativa Background: Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recom­ mended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19. Methods: All adult patients with mild COVID-19 symptoms presented to King Abdulaziz University Hospital, Jeddah, Saudi Arabia, were recruited for an open label randomized clinical trial (RCT). They were randomly divided into control or treatment groups, with the latter receiving 500 mg NSO (MARNYS® Cuminmar) twice daily for 10 days. Symptoms were daily monitored via telecommunication. The primary outcome focused on the percentage of patients who recovered (symptom-free for 3 days) within 14-days. The trial was registered at (NCT04401202). Results: A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53 % of patients were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered patients in NSO group (54[62 %]) was significantly higher than that in the control group (31[36 %]; p = 0.001). The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the control group (12.3 ± 2.8 days); p = 0.001. Conclusions: NSO supplementation was associated with faster recovery of symptoms than usual care alone for patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with placebo-controlled, double-blinded studies.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop